CTMX - CIK 0001501989
CytomX Therapeutics, Inc. trades as CTMX. In its fiscal 2025 annual report the company posted revenue of $76.20M, down 44.8% from the prior year and net income of -$17.37M. This page tracks CytomX Therapeutics, Inc. through 773 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years CytomX Therapeutics, Inc.'s revenue grew from $15.04M to $76.20M, a compound annual growth rate of 19.8%. Net profit margin expanded from -391.5% to -22.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-04-30 |
The largest companies sharing CytomX Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
CytomX Therapeutics, Inc. reported revenue of $76.20M for fiscal year 2025, a decrease of 44.8% year over year.
In its latest fiscal year CytomX Therapeutics, Inc. reported a net loss of $17.37M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.